Ultimate Responsibility for an Investigational Product in Clinical Trials

When a clinical trial uses an investigational product (IP), accountability and oversight rest on a structured framework established by regulatory authorities, sponsors, and investigators. This article explains who has ultimate responsibility for an IP, how duties are delineated, and what each role must manage to ensure safety, compliance, and data integrity throughout the trial lifecycle.

Defining The Investigational Product And Its Core Responsibility

An investigational product refers to a drug, biologic, device, or combination product being studied that has not yet received full regulatory approval for general use. The core responsibility for an IP includes ensuring quality, safety, appropriate labeling, storage, handling, and traceability. This encompasses manufacturing controls, lot disposition, temperature monitoring, and documentation of all IP transfers and usage across trial sites. Clear accountability is essential to protect participant health and meet regulatory expectations.

Sponsor: The Primary Responsible Entity

The sponsor bears the overarching responsibility for the IP from development through regulatory submission. Key duties include:

• Designing the IP management plan, including storage conditions, distribution, and return or destruction at study end.
• Ensuring GMP/GDP compliance in manufacturing, packaging, labeling, and quality control.
• Establishing procedures for IP accountability, chain of custody, and inventory management across sites.
• Providing investigator sites with appropriate IP supply, instructions, and safety information.
• Overseeing safety monitoring and rapid reporting of adverse events related to the IP to regulators and ethics committees.
• Managing regulatory filings, trial registrations, and compliance with applicable laws (e.g., FDA regulations in the United States).

Note: In many trials, sponsors may delegate certain tasks to contract research organizations (CROs) or other entities. Delegation must be clearly defined, documented, and monitored to preserve accountability for IP integrity and regulatory compliance.

Investigator: Site-Level Accountability For IP Handling

The investigator or investigator’s team at each site is responsible for proper IP management during the conduct of the trial. Their responsibilities include:

• Receiving IP shipments, verifying identity and integrity, and ensuring secure storage and proper handling upon receipt.
• Maintaining accurate IP accountability records, including lot numbers, expiration dates, and usage logs.
• Ensuring IP is stored under specified conditions and that access is restricted to authorized personnel.
• Administering the IP per the protocol, providing correct dosing, and documenting administration details and any deviations.
• Monitoring for IP-related safety signals and promptly reporting adverse events or product complaints to the sponsor and ethics committee as required.
• Preventing IP diversion, loss, or unauthorized use, and following procedures for IP return or destruction at the study conclusion.

Important nuance: Delegation is allowed for certain IP-related tasks, but ultimate responsibility remains with the sponsor and is exercised through the investigator’s compliance with protocol and regulatory requirements.

Institutional Obligations And Ethics Committees

Hospitals, universities, and other research institutions hosting trials have their own obligations to ensure IP governance. Responsibilities include:

• Maintaining secure storage facilities and access controls for IP at the site.
• Safeguarding chain-of-custody records and ensuring documentation is complete and auditable.
• Cooperating with monitoring visits, audits, and inspections by regulators and ethics committees.
• Providing informed consent processes that address IP risks, handling, and participant safety.
• Reporting supply chain issues or protocol deviations affecting IP integrity to the sponsor and oversight bodies.

Regulatory Framework In The United States

In the United States, the primary regulatory references shaping IP responsibility include:

• 21 CFR Part 11 and 312 for investigational new drug approvals and safety reporting obligations.
• 21 CFR Part 812 for the regulation of investigational devices, including IP accountability and handling.
• ICH-GCP guidelines, which emphasize the roles of sponsor, investigator, and monitor in protecting human subjects and ensuring data integrity.
• US FDA guidance on IP labeling, packaging, and distribution to ensure traceability and proper use in trials.

Compliance with these rules ensures that IP stewardship aligns with patient safety, ethical standards, and credible data generation.

Practical Scenarios Of Shared And Delegated Responsibility

Understanding how responsibility plays out can prevent gaps in IP oversight. Consider:

• Delegation Of IP Management To A CRO: The sponsor delegates operational tasks, but the sponsor retains ultimate accountability for IP quality, regulatory compliance, and safety reporting.
• Site Transfer Of IP Between Locations: Documentation must track IP movement, confirm storage conditions, and verify receipt by the new site’s personnel with appropriate access.
• Protocol Amendments Impacting IP Use: Any changes affecting dosage, administration route, or storage must be communicated promptly to all sites and reflected in IP handling procedures.
• Safety Events Related To IP: Timely, accurate adverse event reporting to regulators and ethics committees is essential, with clear lines of communication established among sponsor, investigators, and monitoring bodies.

Quality, Safety, And Data Integrity Considerations

Ensuring IP quality involves systematic QA/QC processes, including lot tracing, stability studies, and robust chain-of-custody documentation. Safety considerations require efficient pharmacovigilance, rapid signal detection, and clear escalation protocols. Data integrity hinges on accurate IP records, audit readiness, and monitoring findings that address any deviations in IP handling that could bias results or compromise participant safety.

Key Takeaways For Stakeholders

• The sponsor holds the ultimate responsibility for the IP, including regulatory compliance, manufacturing quality, and distribution controls.
• The investigator bears site-level accountability for IP receipt, storage, administration, and documentation, while adhering to the protocol and regulatory requirements.
• Delegation is permissible but must be clearly defined, with ongoing oversight to preserve accountability and data integrity.
• Regulatory frameworks, including FDA rules and ICH-GCP guidelines, provide the structure for IP governance and safety reporting.
• Effective IP governance requires meticulous documentation, secure storage, traceability, and prompt communication among all parties.